In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Colin Baigent
Colin Baigent
Colin Baigent Colin Baigent

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Speciality : Risk Factors and Prevention

Professor Colin Baigent FMedSci is Director of the MRC Population Health Research Unit and Deputy Director of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford, where he is Professor of Epidemiology. Professor Baigent’s main scientific interests are in the design and conduct of large-scale randomized trials and the use of meta-analysis to assess the efficacy and safety of drugs for treating or preventing cardiovascular disease. He has a particular interest in the epidemiology of CVD in renal failure, and led the Study of Heart and Renal Protection (SHARP), which showed that lowering LDL cholesterol significantly reduced the risk of atherosclerotic events in patients with chronic kidney disease. His group is now coordinating the EMPA KIDNEY trial of empagliflozin vs placebo in 5,000 patients with CKD. He was co-chair of the 2019 ESC/EAS lipid guidelines, and currently chairs the ESC Committee on Practice Guidelines.

8 presentations from this speaker

A 75-year-old patient should be offered a statin for primary prevention - PRO.

Event : ESC Congress 2020

  • Session : Controversies in Cardiovascular Disease Prevention: Statin for Primary Prevention at Age 75
  • Speaker : C Baigent (Bicester,GB)

Management of dyslipidaemia - New 2019 guidelines.

Event : Webinar 2020

  • Session : ESC Webinars 2020
  • Speaker : C Baigent (Bicester,GB), U Landmesser (Berlin,DE), F Perone (Caserta,IT)

Post-myocardial infarction: when to start lipid lowering therapy and how low to go? - What do the Guidelines say.

Event : ESC Congress 2020

  • Session : Guidelines in Practice - Messages from the 2019 ESC Dyslipidemias Guidelines
  • Speaker : C Baigent (Bicester,GB)

2019 ESC/EAS Guidelines on Dyslipidaemias.

Event : ESC Congress 2019

  • Session : 2019 ESC Guidelines Overview
  • Speaker : C Baigent (Bicester,GB), A Catapano (Milan,IT)

Discussant review - THEMIS/THEMIS-PCI

Event : ESC Congress 2019

  • Session : Hot Line Session 1
  • Speaker : C Baigent (Bicester,GB)

Stratifying risk and refining lipid-lowering treatment: an updated approach.

Event : ESC Congress 2019

  • Session : Meet the Task Force of the 2019 ESC/EAS Guidelines on Dyslipidaemias
  • Speaker : C Baigent (Bicester,GB)

Observational studies to inform practice guidelines? .

Event : ESC Congress 2018

  • Session : Evidence to inform practice: promising avenues and dead ends
  • Speaker : C Baigent (Oxford,GB)

Aspirin and cancer prevention: the evidence from randomised clinical trials.

Event : ESC Congress 2014

  • Session : Atherothrombosis and cancer. Common mechanisms, common preventive strategies?
  • Speaker : C Baigent (Oxford,GB)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are